125 related articles for article (PubMed ID: 21820879)
1. Duloxetine's modest short-term influences in subcortical structures of first episode drug-naïve patients with major depressive disorder and panic disorder.
Lai CH; Wu YT
Psychiatry Res; 2011 Nov; 194(2):157-62. PubMed ID: 21820879
[TBL] [Abstract][Full Text] [Related]
2. A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6 weeks' duloxetine therapy.
Lai CH; Hsu YY
Int J Neuropsychopharmacol; 2011 Mar; 14(2):225-35. PubMed ID: 20663271
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine related effects of brain structure on a patient of major depressive disorder with panic disorder.
Lai CH
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):240-1. PubMed ID: 19833160
[No Abstract] [Full Text] [Related]
4. Duloxetine's effects in resting functional magnetic resonance imaging of first-episode, drug-naive major depressive disorder with panic disorder patients.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(3):E10-1. PubMed ID: 21948903
[No Abstract] [Full Text] [Related]
5. First episode drug-naïve major depressive disorder with panic disorder: gray matter deficits in limbic and default network structures.
Lai CH; Hsu YY; Wu YT
Eur Neuropsychopharmacol; 2010 Oct; 20(10):676-82. PubMed ID: 20599363
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E40-1. PubMed ID: 21677224
[No Abstract] [Full Text] [Related]
7. Duloxetine-induced subcortical growth in a patient with major depressive disorder and panic disorder.
Lai CH
J Neuropsychiatry Clin Neurosci; 2011; 23(2):E42-3. PubMed ID: 21677225
[No Abstract] [Full Text] [Related]
8. Hippocampal and subcortical alterations of first-episode, medication-naïve major depressive disorder with panic disorder patients.
Lai CH
J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):142-9. PubMed ID: 24509652
[TBL] [Abstract][Full Text] [Related]
9. Increases in amplitude of low-frequency fluctuations in left fronto-parietal area after duloxetine therapy in first-episode, drug-naïve, major depressive disorder with panic disorder patients.
Lai CH
J Neuropsychiatry Clin Neurosci; 2012; 24(3):E24-5. PubMed ID: 23037667
[No Abstract] [Full Text] [Related]
10. Frontal regional homogeneity increased and temporal regional homogeneity decreased after remission of first-episode drug-naïve major depressive disorder with panic disorder patients under duloxetine therapy for 6 weeks.
Lai CH; Wu YT
J Affect Disord; 2012 Feb; 136(3):453-8. PubMed ID: 22137181
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
15. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
[TBL] [Abstract][Full Text] [Related]
16. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ
J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
18. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study.
Li CT; Lin CP; Chou KH; Chen IY; Hsieh JC; Wu CL; Lin WC; Su TP
Neuroimage; 2010 Mar; 50(1):347-56. PubMed ID: 19931620
[TBL] [Abstract][Full Text] [Related]
19. Time course of depression-symptom improvement during treatment with duloxetine.
Hirschfeld RM; Mallinckrodt C; Lee TC; Detke MJ
Depress Anxiety; 2005; 21(4):170-7. PubMed ID: 16035056
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
